Andreas Bader Has Spent 25 Years Turning Biology Into Biotech

From microRNA to engineered T cells to mitochondrial targets, the Austrian biochemist keeps returning to the same hard problem: how to carry a promising mechanism across the unruly distance between a lab result and a real company.